We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
槐耳颗粒联合 GP 方案治疗晚期非小细胞肺癌的疗效 及对 Th1/Th2 免疫平衡和血清肿瘤标志物的影响.
- Authors
周柏村; 季 欧; 孙 巍; 那琬琳; 姚 权
- Abstract
Objective: To observe the efficacy of gemcitabine combined with cisplatin (GP regimen) combined with Huaier granule in the treatment of advanced non-small cell lung cancer (NSCLC) and its effect on Th1/Th2 immune balance and serum tumor markers. 80 patients with advanced NSCLC who came to Chengdu Sixth People's Hospital for treatment from January 2020 to February 2022 were selected. The patients were divided into control group (40 cases, GP regimen treatment) and study group (40 cases, Huaier granule combined with GP regimen treatment) by double color ball method. The clinical efficacy, serum tumor markers [carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA21-1)], Th1/Th2 immune balance and adverse reactions in the two groups were compared. The objective remission rate and disease control rate in study group were higher than those in control group (P<0.05). There was no difference in incidence of adverse reactions in two groups (P>0. 05). The Karnofsky Performance score (KPS), Th1 and Th1/Th2 in study group after treatment were higher than those in control group (P<0.05), and Th2 was lower than that in control group (P<0.05). The levels of serum CA125, CYFRA21-1 and CEA in study group after treatment were lower than those in control group (P<0.05). Huaier granule combined with GP regimen in the treatment of advanced NSCLC can effectively reduce the levels of serum CA125, CEA and CYFRA21-1 and improve the immune balance of Th1/Th2, which is safe and reliable.
- Subjects
NON-small-cell lung carcinoma; TUMOR markers; IMMUNE serums; BIOMARKERS; CARCINOEMBRYONIC antigen; DISEASE remission
- Publication
Progress in Modern Biomedicine, 2022, Vol 22, Issue 24, p4777
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2022.24.035